Clinical Trials Related to Faron Pharmaceuticals Ltd

Related studies linked through entity extraction aliases.

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Status: WITHDRAWN
Phase: PHASE1

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Status: TERMINATED
Phase: PHASE2

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Status: COMPLETED
Phase: PHASE1/PHASE2

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Status: TERMINATED
Phase: PHASE2

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

Status: TERMINATED
Phase: PHASE3

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

Status: COMPLETED
Phase: PHASE1/PHASE2